A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 62, Issue 1, 2007, Pages 33-41

  Wild, C ^a   Wallner, M ^b   Hufnagl, K ^a   Fuchs, H ^a   Hoffmann Sommergruber, K ^a   Breiteneder, H ^a   Scheiner, O ^a   Ferreira, F ^b   Wiedermann, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Animal model; Mucosal tolerance; Poly sensitization; Recombinant allergen construct; Type I allergy

Indexed keywords

ANTIALLERGIC AGENT; BET V 1 ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10; MESSENGER RNA; PH1 P 1 ANTIGEN; PH1 P 5 ANTIGEN; POLLEN ANTIGEN; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE IMMUNOTHERAPY; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BIRCH; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; GENETIC ENGINEERING; GRASS; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SPLEEN CELL; T LYMPHOCYTE;

ADMINISTRATION, INTRANASAL; ALLERGENS; ANIMALS; BETULA; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HYPERSENSITIVITY; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; POACEAE; POLLEN; RECOMBINANT FUSION PROTEINS; VACCINES, SUBUNIT;

EID: 33845393785     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2006.01245.x     Document Type: Article

References (39)

1. Norman PS. Immunotherapy: 1999-2004. J Allergy Clin Immunol 2004;113:1013-1023.
2. Scheiner O, Kraft D. Basic and practical aspects of recombinant allergens. Allergy 1995;50:384-391.
3. Kagi MK, Wuthrich B. Different methods of local allergen-specific immunotherapy. Allergy 2002;57:379-388.
4. Passalacqua G, Lombardi C, Canonica GW. Sublingual immunotherapy: an update. Curr Opin Allergy Clin Immunol 2004;4:31-36.
5. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446-453.
6. Wiedermann U. Prophylaxis and therapy of allergy and asthma by mucosal tolerance induction with recombinant allergens or allergen constructs. Curr Drug Targets - Inflamm Allergy 2005;4:577-583.
7. Wiedermann U, Jahn-Schmid B, Bohle B, Repa A, Renz H, Kraft D et al. Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen, in a murine model of type I allergy. J Allergy Clin Immunol 1999;103:1202-1210.
8. Winkler B, Baier K, Wagner S, Repa A, Eichler HG, Scheiner O et al. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy 2002;32:30-36.
9. Silvestri M, Rossi GA, Cozzani S, Pulvirenti G, Fasce L. Age-dependent tendency to become sensitized to other classes of aeroallergens in atopic asthmatic children. Ann Allergy Asthma Immunol 1999;83:335-340.
10. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-S334.
11. Hufnagl K, Winkler B, Focke M, Valenta R, Scheiner O, Renz H et al. Intranasal tolerance induction with polypeptides derived from 3 non cross-reactive major aeroallergens prevents allergic polysensitization in mice. J Allergy Clin Immunol 2005;116:370-376.
12. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998;28:914-925.
13. Bergtold A, Desai DD, Gavhane A, Clynes R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 2005;23:503-514.
14. Wiedermann U, Herz U, Baier K, Vrtala S, Neuhaus-Steinmetz U, Bohle B et al. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice. Int Arch Allergy Immunol 2001;126:68-77.
15. Winkler B, Hufnagl K, Spittler A, Ploder M, Kallay E, Vrtala S et al. The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 2006;61:173-180.
16. Sheffield P, Garrard S, Derewenda Z. Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors. Protein Expr Purif 1999;15:34-39.
17. Willerroider M, Fuchs H, Ballmer-Weber BK, Focke M, Susani M, Thalhamer J et al. Cloning and molecular and immunological characterisation of two new food allergens, Cap a 2 and Lyc e 1, profilins from bell pepper (Capsicum annuum) and Tomato (Lycopersicon esculentum). Int Arch Allergy Immunol 2003;131:245-255.
18. Wallner M, Gruber P, Radauer C, Maderegger B, Susani M, Hoffmann-Sommergruber K et al. Lab scale and medium scale production of recombinant allergens in Escherichia coli. Methods 2004;32:219-226.
19. Wopfner N, Willeroidee M, Hebenstreit D, van Ree R, Aalbers M, Briza P et al. Molecular and immunological characterization of profilin from mugwort pollen. Biol Chem 2002;383:1779-1789.
20. Jarolim E, Tejkl M, Rohac M, Schlerka G, Scheiner O, Kraft D et al. Monoclonal antibodies against birch pollen allergens: characterization by immunoblotting and use for single-step affinity purification of the major allergen Bet v 1. Int Arch Allergy Appl Immunol 1989;90:54-60.
21. Repa A, Wild C, Hufnagl K, Winkler B, Bohle B, Pollak A et al. Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy. Clin Exp Immunol 2004;137:12-18.
22. Winkler B, Bolwig C, Seppala U, Spangfort MD, Ebner C, Wiedermann U. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology 2003;110:376-385.
23. Ferreira F, Wallner M, Breiteneder H, Hartl A, Thalhamer J, Ebner C. Genetic engineering of allergens: future therapeutic products. Int Arch Allergy Immunol 2002;128:171-178.
24. Linhart B, Valenta R. Molecular design of allergy vaccines. Curr Opin Immunol 2005;17:646-655.
25. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, Kraft D et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. Faseb J 2002;16:1301-1303.
26. King TP, Jim SY, Monsalve RI, Kagey-Sobotka A, Lichtenstein LM, Spangfort MD. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 2001;166:6057-6065.
27. Kussebi F, Karamloo F, Rhyner C, Schmid-Grendelmeier P, Salagianni M, Mannhart C et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005;115:323-329.
28. Karamloo F, Schmid-Grendelmeier P, Kussebi F, Akdis M, Salagianni M, von Beust BR et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 2005;35:3268-3276.
29. D'Amato G, Spieksma FT, Liccardi G, Jager S, Russo M, Kontou-Fili K et al. Pollen-related allergy in Europe. Allergy 1998;53:567-578.
30. Muller WD, Karamfilov T, Kahlert H, Stuwe HT, Fahlbusch B, Cromwell O et al. Mapping of T-cell epitopes of Phl p 5: evidence for crossreacting and non-crossreacting T-cell epitopes within Phl p 5 isoallergens. Clin Exp Allergy 1998;28:1538-1548.
31. Schenk S, Breiteneder H, Susani M, Najafian N, Laffer S, Duchene M et al. T-cell epitopes of Phl p 1, major pollen allergen of timothy grass (Phleum pratense): evidence for crossreacting and non-crossreacting T-cell epitopes within grass group I allergens. J Allergy Clin Immunol 1995;96:986-996.
32. Hoyne GF, Jarnicki AG, Thomas WR, Lamb JR. Characterization of the specificity and duration of T cell tolerance to intranasally administered peptides in mice: a role for intramolecular epitope suppression. Int Immunol 1997;9:1165-1173.
33. O'Brien RM, Thomas WR, Nicholson I, Lamb JR, Tait BD. An immunogenetic analysis of the T-cell recognition of the major house dust mite allergen Der p 2: identification of high- and low-responder HLA-DQ alleles and localization of T-cell epitopes. Immunology 1995;86:176-182.
34. Millington OR, Mowat AM, Garside P. Induction of bystander suppression by feeding antigen occurs despite normal clonal expansion of the bystander T cell population. J Immunol 2004;173:6059-6064.
35. Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991;174:791-798.
36. Bottcher MF, Haggstrom P, Bjorksten B, Jenmalm MC. Total and allergen-specific immunoglobulin A levels in saliva in relation to the development of allergy in infants up to 2 years of age. Clin Exp Allergy 2002;32:1293-1298.
37. Platts-Mills TA, von Maur RK, Ishizaka K, Norman PS, Lichtenstein LM. IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest 1976;57:1041-1050.
38. Chen YH, Weiner HL. Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance. Ann N Y Acad Sci 1996;778:111-121.
39. Challacombe SJ, Tomasi TB Jr Systemic tolerance and secretory immunity after oral immunization. J Exp Med 1980;152:1459-1472.